OBJECTIVE: The purpose of this study was to evaluate spot scanning proton therapy with an anthropomorphic prostate phantom at the Proton Therapy Center of The University of Texas MD Anderson Cancer Center at Houston, TX (PTCH). METHODS: An anthropomorphic prostate phantom from the Radiological Physics Center (RPC), The University of Texas MD Anderson Cancer Center, Houston, TX, was used, which contained thermoluminescent dosemeters and GAFCHROMIC(®) EBT2 film (ISP Technologies, Wayne, NJ). The phantom was irradiated by the Hitachi synchrotron (Hitachi America, Ltd, Tarrytown, NY), and the results were compared between the treatment planning system (TPS) and RPC measurements. RESULTS: RPC results show that the right/left, inferior/superior and posterior/anterior aspects of the coronal/sagittal and EBT2 film measurements were within ±7%/±4 mm of the TPS. The RPC thermoluminescent dosemeter measurements of the prostate and femoral heads were within 3% of the TPS. CONCLUSION: The RPC prostate phantom is a useful mechanism to evaluate spot scanning beam proton therapy within certain confidence levels. ADVANCES IN KNOWLEDGE: The RPC anthropomorphic prostate phantom could be used to establish quality assurance of spot scanning proton beam for patients with prostate cancer.
OBJECTIVE: The purpose of this study was to evaluate spot scanning proton therapy with an anthropomorphic prostate phantom at the Proton Therapy Center of The University of Texas MD Anderson Cancer Center at Houston, TX (PTCH). METHODS: An anthropomorphic prostate phantom from the Radiological Physics Center (RPC), The University of Texas MD Anderson Cancer Center, Houston, TX, was used, which contained thermoluminescent dosemeters and GAFCHROMIC(®) EBT2 film (ISP Technologies, Wayne, NJ). The phantom was irradiated by the Hitachi synchrotron (Hitachi America, Ltd, Tarrytown, NY), and the results were compared between the treatment planning system (TPS) and RPC measurements. RESULTS: RPC results show that the right/left, inferior/superior and posterior/anterior aspects of the coronal/sagittal and EBT2 film measurements were within ±7%/±4 mm of the TPS. The RPC thermoluminescent dosemeter measurements of the prostate and femoral heads were within 3% of the TPS. CONCLUSION: The RPC prostate phantom is a useful mechanism to evaluate spot scanning beam proton therapy within certain confidence levels. ADVANCES IN KNOWLEDGE: The RPC anthropomorphic prostate phantom could be used to establish quality assurance of spot scanning proton beam for patients with prostate cancer.
Authors: Alfred Smith; Michael Gillin; Martin Bues; X Ronald Zhu; Kazumichi Suzuki; Radhe Mohan; Shiao Woo; Andrew Lee; Ritsko Komaki; James Cox; Kazuo Hiramoto; Hiroshi Akiyama; Takayuki Ishida; Toshie Sasaki; Koji Matsuda Journal: Med Phys Date: 2009-09 Impact factor: 4.071
Authors: Michael T Gillin; Narayan Sahoo; Martin Bues; George Ciangaru; Gabriel Sawakuchi; Falk Poenisch; Bijan Arjomandy; Craig Martin; Uwe Titt; Kazumichi Suzuki; Alfred R Smith; X Ronald Zhu Journal: Med Phys Date: 2010-01 Impact factor: 4.071
Authors: X Ronald Zhu; Yupeng Li; Dennis Mackin; Heng Li; Falk Poenisch; Andrew K Lee; Anita Mahajan; Steven J Frank; Michael T Gillin; Narayan Sahoo; Xiaodong Zhang Journal: Cancers (Basel) Date: 2015-04-10 Impact factor: 6.639